The city of Guangzhou welcomes Singapore Prime Minister Lee Hsien Loong, the first stop of his week-long visit to China. Accompanying PM Lee in this trip are Foreign Minister Vivian Balakrishnan, Trad

April 15, 2023, Biosyngen Pte Ltd (hereinafter as “Biosyngen”) announced that the Company received IND approval for its second product in the pipeline, a T-cell redirection therapy for the treatment o

April 7th, 2023, Biosyngen Pte Ltd (hereinafter as “Biosyngen”) was granted IND approval by China NMPA for the company’s first-in-class T-cell redirection therapy, it is an autologous T cell therapy f

February 16th, 2023, Biosyngen Pte Ltd (hereinafter as "Biosyngen") was granted approval by US FDA for the company's IND application for BRG01 cell therapy, path the way for Phase I/II clinical trial. BRG01 is an autologous T cell therapy for relapsed/metastatic nasopharyngeal cancer (NPC) treatment. The prin...

On Dec. 14th, 2022, Guangzhou Biosyngen Co., Ltd. (hereinafter as “Biosyngen”) made an announcement on the approval granted by the Center for Drug Evaluation (CDE) of China’s National Medical Products

Biosyngen featured in the “Top 50 Most Innovative Companies of Chinese Biomedicine in 2022”, Pharma BigstarOn November 10th to 11th, 2022, the Shanghai (Minhang) Biopharmaceutical Industry Innovation

Prof. Jean Paul Thiery, Biosyngen’s Chief Scientist, is ranked among the World’s Top 2% Clinical Scientists 2022Professor Jean Paul Thiery, Biosyngen’s Chief Scientist and Chairman of Scientific Advis

SINGAPORE, Sept. 28, 2022 /PRNewswire/ — On September 22nd, Biosyngen signed to set up a Cell Therapy GMP Facility which will serve as a bas

SINGAPORE, Sept. 28, 2022 /PRNewswire/ — On September 22nd, Biosyngen signed to set up a Cell Therapy GMP Facility which will serve as a bas